List of Related Excipient Companies and Suppliers of Lumacaftor by Seppic on PharmaCompass.com

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

115 RELATED EXCIPIENT COMPANIES

204EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 936727-05-8, Vx-809, Vx 809, Vx809, Vrt-826809, 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Molecular Formula
C24H18F2N2O5
Molecular Weight
452.4  g/mol
InChI Key
UFSKUSARDNFIRC-UHFFFAOYSA-N
FDA UNII
EGP8L81APK

Lumacaftor
Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes. As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%. A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (F508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with [DB08820] (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and [DB08820] (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals.
The mechanism of action of lumacaftor is as a Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Cytochrome P450 2C8 Inducer, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 2C19 Inducer, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 2C9 Inhibitor, and P-Glycoprotein Inducer, and P-Glycoprotein Inhibitor.
1 2D Structure

Lumacaftor

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
2.1.2 InChI
InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
2.1.3 InChI Key
UFSKUSARDNFIRC-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
EGP8L81APK
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Vx 809

2. Vx-809

3. Vx809

2.3.2 Depositor-Supplied Synonyms

1. 936727-05-8

2. Vx-809

3. Vx 809

4. Vx809

5. Vrt-826809

6. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

7. Vrt 826809

8. Vx-809 (lumacaftor)

9. Egp8l81apk

10. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacid

11. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoic Acid

12. 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic Acid

13. Lumacaftor (usan)

14. 3-(6-{[1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic Acid

15. Lumacaftor [usan]

16. 3-(6-(1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido)-3-methylpyridin-2-yl)benzoic Acid

17. 3-(6-[[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino]-3-methyl-pyridin-2-yl)-benzoic Acid

18. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-be

19. 3-(6-{[1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)benzoic Acid

20. Benzoic Acid, 3-(6-(((1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl)carbonyl)amino)-3-methyl-2-pyridinyl)-

21. Lumacaftor [inn]

22. Lumacaftor [usan:inn]

23. Unii-egp8l81apk

24. Vx8

25. Lumacaftor [mi]

26. Lumacaftor (vx-809)

27. Lumacaftor [who-dd]

28. Lumacaftor(vx-809vx809)

29. Mls006011120

30. Schembl377028

31. Gtpl7481

32. Chembl2103870

33. Lumacaftor [orange Book]

34. Chebi:90951

35. Dtxsid30239523

36. Ex-a178

37. Hms3655e05

38. Orkambi Component Lumacaftor

39. Amy14931

40. Bcp02305

41. Bdbm50289703

42. Mfcd16659051

43. S1565

44. Zinc64033452

45. Akos015920205

46. Lumacaftor Component Of Orkambi

47. Ccg-269253

48. Cs-0479

49. Db09280

50. Pb19466

51. Ncgc00346550-01

52. Ncgc00346550-02

53. Ncgc00346550-05

54. Ac-23172

55. As-31756

56. Hy-13262

57. Smr004702901

58. Ft-0757817

59. Sw219911-1

60. A25628

61. D10134

62. J-690399

63. Q6703005

64. 3-(6-(1-(2,2-difluorobenzo(d) (1,3)dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

65. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) Cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

66. 3-(6-{[1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic Acid; Vx-809

67. 3-(6-{[1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]amino}-3-methyl-pyridin-2-yl)benzoic Acid

2.4 Create Date
2007-08-20
3 Chemical and Physical Properties
Molecular Weight 452.4 g/mol
Molecular Formula C24H18F2N2O5
XLogP34.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass452.11837800 g/mol
Monoisotopic Mass452.11837800 g/mol
Topological Polar Surface Area97.8 Ų
Heavy Atom Count33
Formal Charge0
Complexity776
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

When given in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.


FDA Label


Treatment of cystic fibrosis


5 Pharmacology and Biochemistry
5.1 Pharmacology

Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ [DB08820]) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, reduced sweat chloride, increased weight gain, and improvements in CF symptoms and quality of life. Orkambi was not found to increase the QTc interval to any clinically relevant extent.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
LUMACAFTOR
5.2.2 FDA UNII
EGP8L81APK
5.2.3 Pharmacological Classes
Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors
5.3 ATC Code

R07AX30

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


5.4 Absorption, Distribution and Excretion

Absorption

Following administration of Orkambi (lumacaftor/[DB08820]) with fat containing foods, peak plasma concentrations were reached at 4 hours (Tmax). It's recommended that Orkambi should be taken with fat-containing foods as they increase absorption of lumacaftor by approximately 2-fold, and[DB08820 by 3-fold.


Route of Elimination

Lumacaftor is primarily excreted unchanged in the feces (51%). A minimal amount of the parent compound and its metabolites are excreted in the urine.


Volume of Distribution

Following oral administration of 200 mg of lumacaftor every 24 hours to cystic fibrosis patients in a fed state for 28 days, the mean (+/-SD) for apparent volumes of distribution was 86.0 (69.8) L.


Clearance

The typical apparent clearance, CL/F (CV), of lumacaftor was estimated to be 2.38 L/hr.


5.5 Metabolism/Metabolites

Lumacaftor is mostly excreted unchanged in the feces and is not extensively metabolized. When metabolism does occur, oxidation and glucuronidation are the main processes involved.


5.6 Biological Half-Life

The half-life of lumacaftor is approximately 26 hours.


5.7 Mechanism of Action

Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. More specifically, lumacaftor acts as a protein-folding chaperone, preventing misfolding of CFTR ion channels and consequent destruction during processing in the endoplasmic reticulum.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667586600,"product":"LUMACAFTOR","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE ","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KING PRIME GLOBAL PROCUREMENT TRADI","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"24","totalValueFC":"11775.1","currency":"EUR","unitRateINR":1922,"date":"05-Nov-2022","totalValueINR":"961000","totalValueInUsd":"11775.1","indian_port":"BOMBAY AIR","hs_no":"29163190","bill_no":"5277111","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""}]
05-Nov-2022
05-Nov-2022
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Lubricants & Glidants

read-more
read-more

Granulation

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Parenteral

read-more
read-more

Taste Masking

read-more
read-more

Coloring Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty